Nanoparticles in Cancer Therapy and Diagnosis
Transcript of Nanoparticles in Cancer Therapy and Diagnosis
![Page 1: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/1.jpg)
Nanoparticles Applications in Cancer Therapy and
Diagnosis
By: M. Shafiee
PhD student, Biochemistry Department, Shiraz
University of Medical Sciences, November 2008.
![Page 2: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/2.jpg)
Nanotechnology• 1st trigger: by the Nobel Laureate, R. Feynman in
1959:
“Using larger machines to manufacture smaller ones”
• N. Taniguchi, 1974: used the term “nano”, meaning “dwarf”.
• The principle: engineering and manufacturing of systems or device at the molecular level.
![Page 3: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/3.jpg)
Nanotechnology (cont…)
![Page 4: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/4.jpg)
Nanotechnology (cont...)• Understanding and control of matter at
dimensions of 1 to 100 nanometer, sometimes up to 500 nm.
• Multidisciplinary, using bio-nonomaterials in engineering or engineered nanomaterials in biology and medicine.
• Different aspects:• Nanomaterials • Nanodevices• Nanosystems
![Page 5: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/5.jpg)
Nanoparticles in medicine
Using nanoscale-sized structures for:
• Treatment (drug/gene delivery, etc.)
• Diagnosis and screening
• Tissue engineering
![Page 6: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/6.jpg)
Basic concepts of NPs
• Bulk properties of materials in nano-sized structure differ significantly from the original material.
• Altering the size of building blocks can controle internal and surface chemistry, electrical conductivity, magnetic properties etc…
![Page 7: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/7.jpg)
NPs and Cancer
• Apply the interaction of NPs with cellular and molecular components for:
1-Cancer diagnosis
2-Cancer therapy: a. Systemic administration
b. Local administration
![Page 8: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/8.jpg)
Targeting to Cancer
• Targeting to neovasculature
• Targeting to cancer cells:
1- Passive targeting
2- Active targeting
![Page 9: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/9.jpg)
Passive targeting• Is related to different characteristics of
neoplasm tissue:
1-Open gaps through interendothelial channels.
2-Less lymphatic drainage.
• NPs Cause enhanced permeability and retention effect (EPR).
• So in the reticuloendothelial system (RES) the uptake should be avoided.
![Page 10: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/10.jpg)
Active targeting
• By specific interactions:
Antigen-antibody
Ligand-receptors
• Targeted to:
Angiogenesis
Tumor vasculature
Cancer cells specific antigen
![Page 11: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/11.jpg)
Common targets in Active targeting
• VEGF receptors.
• Integrins, e.g. αvβ3 by NPs with RGD.
• Folate receptor (overexpressed in various epithelial cancer cells).
• EGF receptor.
• Specific tumor Ag, such as PSA.
• Surface carbohydrates, using lectins.
![Page 12: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/12.jpg)
Various types of NPs• From last 2 decades:
Gelatin, Ceramic, Liposomes, Micelles
• More recently:
Conventional polymeric NPs
Long-circulating polymeric NPs
Quantum Dots (QDs)
Dendrimers
Aptamers
Metallic and Magnetic NPs
![Page 13: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/13.jpg)
Conventional polymeric NPs
![Page 14: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/14.jpg)
![Page 15: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/15.jpg)
Conventional polymeric NPs for passive drug delivery
• Incorporation of drugs to polymers.
e.g PIHCA [poly(isohexylcyanoacrylate] with
doxorubicin.
Hydrophobicity causes the uptake by liver,
spleen and lung and higher conc. in these
organs in compare with free doxorubicin.
![Page 16: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/16.jpg)
Conventional polymeric NPs advantages
• Hepatocarcinomas and metastasis to liver.
Drug accumulation in Kupffer cells’ lysosomes makes a reservoir for gradient and gradual release.
• Treatment of some lymphomas.
![Page 17: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/17.jpg)
Conventional polymeric NPs disadvantages
• By targeting the BM cause myelosuppressive effects.
• Renal toxicity due to mesengial cells uptake and glomerolar damage.
• Cardiotoxicity.
• Short circulating time due to uptake by RES.
![Page 18: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/18.jpg)
Long-circulating NPs
![Page 19: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/19.jpg)
Hydrophilic coat
Modifications in long-circulating polymeric NPs
![Page 20: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/20.jpg)
Long-circulating NPs• “Stealth” particles invisible to macrophages.
• Directly target tumors outside of MPS.
• Modifications: Size < 100 nm
Hydrophilic Surface
• Repel plasma proteins and prevent opsonization.
• Improving circulation time.
• More extravasation and retention.
![Page 21: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/21.jpg)
Long-circ. NPs (cont…)
• A dynamic cloud of hydrophilic chains is made by:
1-Adsorption of surfactants.
e.g. Poloxamine, Polysorbate 80
2-Use of block or branched polymers.
e.g. polyethylene glycol (PEG) and Pluronic.
![Page 22: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/22.jpg)
Schematic of enhanced permeability and retention effect.
![Page 23: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/23.jpg)
Quantum Dots
![Page 24: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/24.jpg)
QDs
![Page 25: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/25.jpg)
Quantum Dots
• Nanocrystals composed of a core of a
semiconductor material (CdSe), enclosed within
a shell of another semiconductor (ZnS) that has
a larger spectral band gap.
Spectral band gap: the separation between electronic energy
levels of a material.
![Page 26: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/26.jpg)
QDs characteristics
• Diameter of about 2–10 nm, allows one-on-one
interaction with biomolecules such as proteins.
• Inorganic fluorophores that have size-tunable
emission.
• Strong light absorbance.
• Bright fluorescence.
• High photostability.
![Page 27: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/27.jpg)
QDs’ applications
• Imaging and detection
• Therapy
![Page 28: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/28.jpg)
Multicolor quantum dot (QD) capability of QD imaging in live animal, using 3 different QDs with the same wavelength in deep organs.
![Page 29: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/29.jpg)
specific mAb attachment to the QD
![Page 30: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/30.jpg)
QDs for imaging and diagnosis
• QDs emit in the IR and near-IR regions, imaging
and diagnostic of cells deep within tissues.
• Long-term and real time imaging due to stability.
• mAb conjugated QDs to detect specific tumor Ags
and tumor site detection.
![Page 31: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/31.jpg)
Schematic concept of single-QD-based DNA probe. FRET= Fluorescence resonance energy transfer
Emission (QD)605 nm
Excitation488 nm
Emission Cy5670 nm
FRET
![Page 32: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/32.jpg)
)C (Fluorescent images of QDs (top), Cy5 (middle) and merged colors (bottom) with complementary DNA target and (D) non-complementary DNA target.
![Page 33: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/33.jpg)
Dendrimers
![Page 35: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/35.jpg)
Dendrimers
• The Greek word dendron, meaning "tree".
• Repeatedly branched, monodisperse, and usually highly symmetric globular compounds.
• The branching units are described by generation.
• Characterized by their terminal generation, e.g. a G5 dendrimer refers to a polymer with four generations.
![Page 36: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/36.jpg)
Dendrimers
(1) PAMAM. (polyamidoamine dendrimer).(3) Bow tie dendrimer based on 2,2-bis(hydroxymethyl) propionic acid.
![Page 37: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/37.jpg)
Interaction of PAMAM dendrimers with lipid bilayers.
![Page 38: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/38.jpg)
Dendrimers’ pharmacokinetics
• Can be tuned by varying generation size and the rate of PEGylation, esp. in bow tie forms.
![Page 39: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/39.jpg)
Drug delivery by dendrimers
• Non-covalent encapsulation in the interior of the dendrimer.
• Covalently conjugation to form macromolecular prodrugs.
![Page 40: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/40.jpg)
Dendrimer-drug conjugates
• Antineoplastic agent covalently attached to the peripheral groups of the dendrimer.
e.g. carboxylate-terminated G3 PAMAM conjugated with MTX, is 24-fold more effective than free MTX on MTX resistant cell lines.
![Page 41: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/41.jpg)
Dendrimers for targeted drug delivery and imaging
A G5-PAMAM conjugated anti-HER2 mAb targets tumors that overexpress HER2.
Drug
![Page 42: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/42.jpg)
Dendrimers for photothermal therapy
• Gold-based NPs strongly absorb light in the near-IR region.
• Facilitating deep optical penetration into tissues.
• Generating a localized lethal dose of heat at the site of a tumor.
• Only within the last year (2007), dendrimer-encapsulated gold nanoparticles prepared and identified for the photothermal treatment of malignant tissue.
![Page 43: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/43.jpg)
Photothermal therapy
Photothermal therapy using dendrimer-entrapped gold nano-particles.
![Page 44: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/44.jpg)
Aptamers
![Page 45: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/45.jpg)
Aptamers
• The Latin word “aptus”, means “to fit.”
• Single-stranded DNA, RNA, or unnatural oligonucleotides that fold into unique structures capable of binding to specific targets with high affinity and specificity.
• Unlike anti-sense oligonucleotides (siRNA), bind and inhibit different types of targets directly.
![Page 46: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/46.jpg)
Aptamers’ advantages
• Small size (~5 nm for 30–60 base pair of aptamer).
• Highly stable in wide range of temperature and pH (~4-9).
• No batch-to-batch variations in compare with mAbs.
![Page 47: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/47.jpg)
Aptamers production
• SELEX
“ Systematic evolution of ligands by exponential enrichment”
• A selection and amplification protocol to isolate single-stranded nucleic acid ligands that bind to their target with high affinity and specificity.
![Page 48: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/48.jpg)
Aptamer–NP conjugates
Long-circ. NP
![Page 49: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/49.jpg)
Aptamer–NP conjugates for targeted cancer therapy and diagnosis
• Conjugation to drug encapsulated NPs.
• Binding to optical imaging agents including:
Fluorophores
QDs (nanocrystals)
MRI imaging agents such as magnetic nanoparticles.
![Page 50: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/50.jpg)
Aptamer-drug conjugates for targeted drug delivery
PSA aptamer
Doxorubicin
Interaction
Physical conjugate
+
![Page 51: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/51.jpg)
Conclusion
• NP-based therapeutics for clinical use:
1. Approved for clinical use.
e.g. PEGylated NPs such as PEG-anti VEGF aptamer
2. In clinical trial period.
e.g. Pluronic block-copolymer doxorubicin, in phase II
3. In preclinical development period.
e.g. foliate-PAMAM dendrimers
![Page 52: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/52.jpg)
• Main references: 1. Lisa Brannon-Peppas, James O. Blanchette, Nanoparticle and
targeted systems for cancer therapy, Advanced Drug Delivery Reviews 56 (2004) 1649– 1659.
2. Jesse B. Wolinsky, Mark W. Grinstaff, Therapeutic and diagnostic applications of dendrimers for cancer treatment, Advanced Drug Delivery Reviews 60 (2008) 1037–1055.
3. Hassan M.E. Azzazy , Mai M.H. Mansour , Steven C. Kazmierczak, From diagnostics to therapy: Prospects of quantum dots, Clinical Biochemistry 40 (2007) 917–927.
4. Omid C. Farokhzad, Sangyong Jon, and Robert Langer, Aptamers and Cancer Nanotechnology, 2006 by Taylor & Francis Group, LLC, pp 289-306.
5. Tania Betancourt, Amber Doiron,and Lisa Brannon-Peppas, Polymeric Nanoparticles for Tumor-Targeted Drug Delivery, 2006 by Taylor & Francis Group, LLC, pp 215-226.
![Page 53: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/53.jpg)
• Main references (cont…): 6. Sushma Kommareddy, Dinesh B. Shenoy, and Mansoor M. Amiji,
Long-Circulating Polymeric Nanoparticles for Drug and Gene Delivery to Tumors, 2006 by Taylor & Francis Group, LLC, pp 231-239.
7. Hassan M.E. Azzazy , Mai M.H. Mansour , Steven C. Kazmierczak, From diagnostics to therapy: Prospects of quantum dots, Clinical Biochemistry 40 (2007) 917–927.
8. Noritada KAJI, Manabu TOKESHI, and Yoshinobu BABA, Quantum Dots for Single Bio-Molecule Imaging, ANALYTICAL SCIENCES JANUARY 2007, VOL. 23, pp 21-24.
9. Lisa Brannon-Peppas, James O. Blanchette, Nanoparticle and targeted systems for cancer therapy, Advanced Drug Delivery Reviews 56 (2004) 1649– 1659.
![Page 54: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/54.jpg)
![Page 55: Nanoparticles in Cancer Therapy and Diagnosis](https://reader035.fdocuments.net/reader035/viewer/2022062404/55287de1550346e06e8b47b2/html5/thumbnails/55.jpg)
Thank You